期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 54, 期 -, 页码 24-31出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2020.06.008
关键词
COVID-19; SARS-CoV-2; Pulmonary inflammation; Cytokine storm; Immune cells; Interleukin-15
资金
- Edward G. Schlieder Educational Foundation
- [NIHR01 AI080581]
Coronavirus disease 2019 (COVID-19) is a pulmonary inflammatory disease induced by a newly recognized coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection was detected for the first time in the city of Wuhan in China and spread all over the world at the beginning of 2020. Several millions of people have been infected with SARS-CoV-2, and almost 382,867 human deaths worldwide have been reported so far. Notably, there has been no specific, clinically approved vaccine or anti-viral treatment strategy for COVID-19. Herein, we review COVID-19, the viral replication, and its effect on promoting pulmonary fibro-inflammation via immune cell-mediated cytokine storms in humans. Several clinical trials are currently ongoing for anti-viral drugs, vaccines, and neutralizing antibodies against COVID-19. Viral clearance is the result of effective innate and adaptive immune responses. The pivotal role of interleukin (IL)-15 in viral clearance involves maintaining the balance of induced inflammatory cytokines and the homeostatic responses of natural killer and CD8(+) T cells. This review presents supporting evidence of the impact of IL-15 immunotherapy on COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据